Media stories about Cerus (NASDAQ:CERS) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerus earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.778098067388 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

CERS has been the subject of a number of analyst reports. Robert W. Baird restated a “buy” rating and issued a $5.00 price target on shares of Cerus in a research note on Friday, December 1st. Zacks Investment Research upgraded Cerus from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research note on Wednesday, November 8th. Cantor Fitzgerald restated a “buy” rating and issued a $5.00 price target on shares of Cerus in a research note on Tuesday, January 23rd. BTIG Research restated a “hold” rating on shares of Cerus in a research note on Thursday, January 25th. Finally, BidaskClub upgraded Cerus from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $5.83.

Shares of Cerus (CERS) opened at $4.60 on Friday. Cerus has a 52-week low of $1.93 and a 52-week high of $5.43. The stock has a market capitalization of $608.08, a P/E ratio of -7.79 and a beta of 2.16. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with's FREE daily email newsletter.